Pulmatrix (NASDAQ: PULM) Investor Presentation 9/5/2018
Pulmatrix Corporate Overview (2018.08) – final for website
Pulmatrix (NASDAQ: PULM) Investor Presentation
Healthcare
CytoDyn (OTC: CYDY) Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV
VANCOUVER, Washington and NEW YORK, Dec 17, 2019 – In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, Vyera will pay upfront and regulatory and sales-based milestone […]
Newsmakers
CytoDyn’s (OTC: CYDY) Lead Product Candidate Leronlimab (PRO 140) Inhibits Colon Carcinoma Metastases to Liver and Lung in Preclinical Studies
CytoDyn will file for expanded access IND for patients with pancreatic, prostate, lung, breast, liver and melanoma cancers VANCOUVER, Washington, Nov 19, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology […]
Healthcare
CytoDyn (OTC: CYDY) Finalizes Development of Receptor Occupancy Test to Guide Pivotal Monotherapy Discussions With the FDA
VANCOUVER, Washington, Jul 25, 2019– – FDA face-to-face meeting granted to discuss pivotal monotherapy trial – Conference call for investors and media on Tuesday, July 30, 2019 at 4:00 p.m. ET with introduction to Dr. […]